Skip to main content

Table 1 Study samples (DNA extracted from culture isolates) and their susceptibility to anti-tuberculosis drugs

From: The variability and reproducibility of whole genome sequencing technology for detecting resistance to anti-tuberculous drugs

Sample Yeara Lineage Spoligo. family Drug susceptibility test phenotype
INH RIF STR ETB PZA RFB ETH AMK CAP OFX MOX PAS LZ KANb Resistance phenotype
POR1 2007 4.3.4.2 LAM4 R R R R R R R R R R R R S R XDR-TB
POR2 2007 4.1.1.1 X2 R R S S S R R S S S S S S - MDR-TB
POR3 2007 4.3.4.2 LAM1 R R R R R R R R R R R S S R XDR-TB
POR4 2007 4.3.4.2 LAM1 R R R R R R R R S R R S S R XDR-TB
POR5 2007 4.3.4.2 LAM4 R R R R R R R S S S S S S - MDR-TB
POR6 2008 4.3.4.2 LAM4 R R R R R R R R R R R S S R XDR-TB
POR7 2009 4.3.4.2 LAM4 R R R R R R R R R R R S S R XDR-TB
POR8 2012 4.3.4.2 LAM4 R R R R R R R R R R R S S R XDR-TB
POR9 2011 4.3.4.2 LAM4 R R R R R R R R R R R R S R XDR-TB
POR10 2013 4.2.1 Ural H3/4 R R R R R R R S S S S S S R MDR-TB
H37Rv - 4.9 H37RV S S S S S S S S S S S S S - Pan-susceptible
  1. MDR-TB multidrug-resistant TB, XDR-TB extensively drug-resistant TB, INH isoniazid, RIF rifampicin, STR streptomycin, ETB ethambutol, PZA pyrazinamide, RFB rifabutin, ETH ethionamide, AMK amikacin, CAP capreomycin, OFX ofloxacin, MOX moxifloxacin, PAS para-aminosalicylic acid, LZ linezolid, KAN kanamycin, S “susceptible”, R “resistant”
  2. Bold indicates discrepant calls by Mykrobe Predictor, underlining indicates discrepant calls by TBProfiler
  3. aYear of collection
  4. bDrug susceptibility test not performed, with status inferred by the TBProfiler library